Recognition and reporting of suspected adverse drug reactions by surveyed healthcare professionals in Uganda: Key determinants

BMJ Open

Volumn 4, Issue , 2014, Pages

  Kiguba, Ronald ^a   Karamagi, Charles ^a   Waako, Paul ^a   Ndagije, Helen B ^b   Bird, Sheila M ^c  

^a MAKERERE UNIVERSITY   (Uganda)

^b National Drug Authority   (Uganda)

^c MRC BIOSTATISTICS UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; QUININE;

ADULT; ADVERSE DRUG REACTION; ARTICLE; AWARENESS; CONTROLLED STUDY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; HEALTH CARE FACILITY; HEALTH CARE PERSONNEL; HEALTH SURVEY; HOSPITAL PERSONNEL; HUMAN; LETHARGY; MALE; MULTICENTER STUDY; NON PROFIT HOSPITAL; NURSE; PRIVATE PRACTICE; PUBLIC HEALTH; PUBLIC HOSPITAL; RISK FACTOR; UGANDA; UNSPECIFIED SIDE EFFECT; CROSS-SECTIONAL STUDY; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH PERSONNEL; HUMANS; MALE; PHARMACOVIGILANCE; SURVEYS AND QUESTIONNAIRES; UGANDA;

EID: 84979862565     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005869     Document Type: Article

References (61)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279:1200-5.
2. Ramesh M, Pandit J, Parthasarathi G. Adverse drug reactions in a south Indian hospital - their severity and cost involved. Pharmacoepidemiol Drug Saf 2003; 12:687-92.
3. Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277:301-6.
4. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 1997; 277:307-11.
5. Gautier S, Bachelet H, Bordet R, et al. The cost of adverse drug reactions. Expert Opin Pharmacother 2003; 4:319-26.
6. World Health Organization. The Safety of Medicines in Public Health Programmes: Pharmacovigilance an Essential Tool. 2006. http://www.who.int/medicines/areas/quality-safety/safety-efficacy/Pharmacovigilance-B.pdf (accessed 31 May 2014).
7. Lexchin J. Is there still a role for spontaneous reporting of adverse drug reactions? CMAJ 2006; 174:191-2.
8. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf 2009; 32:19-31.
9. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 29:385-96.
10. Smith CC, Bennett PM, Pearce HM, et al Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol 1996; 42:423-9.
11. Pirmohamed M, Breckenridge AM, Kitteringham NR, et al. Adverse drug reactions. BMJ 1998; 316:1295-8.
12. Gavaza P, Brown CM, Lawson KA, et al. Influence of attitudes on pharmacists' intention to report serious adverse drug events to the Food and Drug Administration. Br J Clin Pharmacol 2011; 72:143-52.
13. Miguel A, Azevedo LF, Lopes F, et al. Methodologies for the detection of adverse drug reactions: comparison of hospital databases, chart review and spontaneous reporting. Pharmacoepidemiol Drug Saf 2013; 22:98-102.
14. Alj L, Touzani MDW, Benkirane R, et al. Detecting medication errors in pharmacovigilance database: Capacities and limits. Int J Risk Saf Med 2007; 19:187-94.
15. Strengthening Pharmaceutical Systems (SPS). Supporting pharmacovigilance in developing countries: the systems perspective. Arlington, VA: Submitted to the U.S. Agency for International Development by the SPS Program, 2009.
16. Isah AO, Pal SN, Olsson S, et al. Specific features of medicines safety and pharmacovigilance in Africa. TherAdv Drug Saf 2012; 3:25-34.
17. National Pharmacovigilance Centre. Working together with the Public Health Programmes: a regulator's perspective for addressing the minimum requirements for Pharmacovigilance. 2010. http://www.who.int/medicines/areas/quality-safety/regulation-legislation/icdra/WG-2-2Dec.pdf (accessed 21 Jun 2013).
18. Institute for Health Metrics and Evaluation. The global burden of disease: generating evidence, guiding policy-sub-Saharan Africa Regional Edition. 2013. http://www.healthdata.org/policy-report/global-burden-disease-generating-evidence-guiding-policy%E2%80%94sub-saharan-africa-regional (accessed 31 May 2014).
19. Uppsala Monitoring Centre (UMC). VigiFlow™ The complete Individual Case Safety Report (ICSR) management system from the UMC. http://www.who-umc.org/graphics/27705.pdf (accessed 31 May 2014).
20. Uppsala Monitoring Centre (UMC). Pharmacovigilance - reporting trends. 2013. http://who-umc.org/DynPage.aspx?id=108476&mn1=7347&mn2=7252&mn3=7322&mn4=7558 (accessed 31 May 2014).
21. Strengthening Pharmaceutical Systems (SPS) Program. Safety of medicines in sub-Saharan Africa: assessment of pharmacovigilance systems and their performance. 2011. http://apps.who.int/medicinedocs/documents/s19152en/s19152en.pdf2014
22. Ouma C, Abwao E. Africa Pharmacovigilance Meeting 2012: Technical Report. Submitted to the US Agency for International Development by the Systems for Improved Access to Pharmaceuticals and Services Program, 2012.
23. National Pharmacovigilance Centre. The Pharmacovigilance News. 2010. http://www.nda.or.ug/docs/bulletin%20issue%20No.1.pdf (accessed 1 Jun 2014).
24. Appiah B. Africa struggles to improve drug safety. CMAJ 2012; 184: E533-4.
25. Ekure J. Gluteal fibrosis. A report of 28 cases from Kumi Hospital, Uganda. East Cent Afr J Surg 2006; 12:144-7.
26. Ekure J. Post-injection paralysis: the new polio in Uganda. 9 December 2007. http://www.newvision.co.ug/D/9/34/601055.
27. Chinnock P. Concern in Uganda over children injured by poorly administered malaria treatment. 2009. http://www.tropika.net/svc/news/20090604/Chinnock-20090604-News-Quinine-Uganda (accessed 13 May 2014).
28. National Pharmacovigilance Centre. What is current practice of Pharmacovigilance in Uganda? 2012. http://africapv2012.files.wordpress.com/2012/04/day-2-5-country-presentations-nras-h-ngadije-uganda-compatibility-mode.pdf (accessed 11 Dec 2013).
29. Bateman DN, Sanders GL, Rawlins MD. Attitudes to adverse drug reaction reporting in the Northern Region. Br J Clin Pharmacol 1992; 34:421-6.
30. Figueiras A, Tato F, Fontainas J, et al. Influence of physicians' attitudes on reporting adverse drug events: a case-control study. Med Care 1999; 37:809-14.
31. Rawlins MD Pharmacovigilance: paradise lost, regained or postponed? The William Withering Lecture 1994. J R Coll Physicians Lond 1995; 29:41-9.
32. Inman WH Attitudes to adverse drug reaction reporting. Br J Clin Pharmacol 1996; 41:434-5.
33. Herdeiro MT, Figueiras A, Polonia J, et al. Physicians' attitudes and adverse drug reaction reporting: a case-control study in Portugal. Drug Saf 2005; 28:825-33.
34. Oshikoya KA, Awobusuyi JO. Perceptions of doctors to adverse drug reaction reporting in a teaching hospital in Lagos, Nigeria. BMC Clin Pharmacol 2009; 9:14.
35. Robins AH, Weir M, Biersteker EM. Attitudes to adverse drug reactions and their reporting among medical practitioners. S Afr Med J 1987; 72:131-4.
36. Ball D, Tisocki T. Adverse drug reaction reporting by general medical practitioners and retail pharmacists in Harare - a pilot study. Cent Afr J Med 1998; 44:190-5.
37. Okezie EO, Olufunmilayo F. Adverse drug reactions reporting by physicians in Ibadan, Nigeria. Pharmacoepidemiol Drug Saf 2008; 17:517-22.
38. Jaquet A, Djima MM, Coffie P, et al. Pharmacovigilance for antiretroviral drugs in Africa: lessons from a study in Abidjan, Cote d'Ivoire. Pharmacoepidemiol Drug Saf 2011; 20:1303-10.
39. Africa Health Workforce Observatory. Human Resources for Health Country Profile - Uganda. 2009:30.
40. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009; 338:b2393.
41. StataCorp. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP, 2011.
42. Khan SA, Goyal C, Chandel N, et al. Knowledge, attitudes, and practice of doctors to adverse drug reaction reporting in a teaching hospital in India: an observational study. J Nat Sci Biol Med 2013; 4:191-6.
43. Pimpalkhute SA, Jaiswal KM, Sontakke SD, et al. Evaluation of awareness about pharmacovigilance and adverse drug reaction monitoring in resident doctors of a tertiary care teaching hospital. Indian J Med Sci 2012; 66:55-61.
44. Bemt van den PMLA, Egberts ACG. Drug-related problems: definitions and classifications. EJHP 2007; (13):62-4.
45. Gallagher TH, Waterman AD, Ebers AG, et al. Patients' and physicians' attitudes regarding the disclosure of medical errors. JAMA 2003; 289:1001-7.
46. Cox AR, Marriott JF, Wilson KA, et al. Adverse drug reaction teaching in UK undergraduate medical and pharmacy programmes. J Clin Pharm Ther 2004; 29:31-5.
47. Cross C. Drug reporting may be mandatory for doctors. CMAJ 2013; 185:866.
48. Uppsala Monitoring Centre. Uppsala Reports 59. 2012.
49. Herxheimer A, Crombag R, Alves TL. Direct Patient Reporting of Adverse Drug Reactions. May 2010. http://www.haiweb.org/14012010/14Jan2010ReportDirectPatientReportingofADRsFINAL.pdf
50. Masso Guijarro P, Aranaz Andres JM, Mira JJ, et al. Adverse events in hospitals: the patient's point of view. Qual Saf Health Care 2010; 19:144-7.
51. Bukirwa H, Nayiga S, Lubanga R, et al. Pharmacovigilance of antimalarial treatment in Uganda: community perceptions and suggestions for reporting adverse events. Trop Med Int Health 2008; 13:1143-52.
52. Tubert-Bitter P, Haramburu F, Begaud B, et al. Spontaneous reporting of adverse drug reactions: who reports and what? Pharmacoepidemiol Drug Saf 1998; 7:323-9.
53. Irujo M, Beitia G, Bes-Rastrollo M, et al. Factors that influence under-reporting of suspected adverse drug reactions among community pharmacists in a Spanish region. Drug Saf 2007; 30:1073-82.
54. Ohaju-Obodo JO, Iribhogbe OI. Extent of pharmacovigilance among resident doctors in Edo and Lagos states of Nigeria. Pharmacoepidemiol Drug Saf 2010; 19:191-5.
55. Li Q, Zhang SM, Chen HT, et al. Awareness and attitudes of healthcare professionals in Wuhan, China to the reporting of adverse drug reactions. Chin Med J (Engl) 2004; 117:856-61.
56. Chatterjee S, Lyle N, Ghosh S. A survey of the knowledge, attitude and practice of adverse drug reaction reporting by clinicians in Eastern India. Drug Saf 2006; 29:641-2.
57. Aagaard L, Strandell J, Melskens L, et al. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase. Drug Saf2012; 35:1171-82.
58. Passier A, ten Napel M, van Grootheest K, et al. Reporting of adverse drug reactions by general practitioners: a questionnairebased study in the Netherlands. Drug Saf2009; 32:851-8.
59. Herdeiro MT, Figueiras A, Polonia J, et al. Influence of pharmacists' attitudes on adverse drug reaction reporting: a case-control study in Portugal. Drug Saf 2006; 29:331-40.
60. Herdeiro MT, Polonia J, Gestal-Otero JJ, et al. Factors that influence spontaneous reporting of adverse drug reactions: a model centralized in the medical professional. J Eval Clin Pract 2004; 10:483-9.
61. World Health Organization (WHO) - MMV joint technical consultation on active pharmacovigilance monitoring with a special focus on affordable medicine facility for malaria (AMFm). Pharmacovigilance Guidance for Countries Participating in AMGm Phase 1. 2009. http://apps.who.int/medicinedocs/documents/s18427en/s18427en.pdf (accessed 1 Jun 2014).